Sjögren’s Syndrome Market Faces Decade of Transformation

The current treatment landscape relies heavily on medications like pilocarpine and cevimeline, which address dryness but fail to halt the broader systemic pathology. According to industry analysis, this gap in care has spurred intensive clinical activity. Major pharmaceutical players, including Amgen, Johnson & Johnson, and Novartis, are advancing a pipeline of candidates designed to modulate B-cell activity and reduce pathogenic autoantibodies.

Emerging Therapies and Clinical Progress

Key assets such as Telitacicept, Dazodalibep, and Nipocalimab represent a new generation of disease-modifying therapies currently navigating mid-to-late-stage clinical trials. Among these, Ianalumab has garnered attention for its dual mechanism and FDA Breakthrough Therapy designation, positioning it as a potential catalyst for a new standard of care. As these therapies progress through global trials, the market is expected to see sustained growth through 2036, driven by higher diagnostic rates and the introduction of advanced biologic treatments. The United States currently holds the largest share of the treatment market, a trend projected to continue as these targeted therapies move toward commercialization.